Showing 2151-2160 of 2890 results for "".
- Alastin Skincare Scores Another New Patenthttps://modernaesthetics.com/news/alastin-skincare-scores-another-new-patent/2472970/Alastin Skincare, Inc. received a fourth U.S. Patent from the United States Patent and Trademark Office. The new patent, which incorporates TriHex Technology, is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum
- Restylane Kysse Shows Positive Kissability Satisfaction in Phase 4 Studyhttps://modernaesthetics.com/news/restylane-kysse-shows-positive-kissability-satisfaction-in-phase-4-study/2472966/In a first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, researchers evaluated subject satisfaction as well as partner satisfaction following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- New from Cutera: Get to Know Fraxis PROhttps://modernaesthetics.com/news/new-from-cutera-get-to-know-fraxis-pro/2472965/Cutera, Inc. is launching Fraxis PRO progressive dermal remodeling technology. Fraxis PRO combines fractional CO2 for skin resurfacing and radiofrequency microneedling for dermal remodeling in a single device. Fraxis PRO treats: Fine Lines Wr
- Allergan Donates $300K to Bridge the Gender Gap in STEMhttps://modernaesthetics.com/news/allergan-donates-300k-to-bridge-the-gender-gap-in-stem/2472964/Allergan has pledged $300K to support STEM Education through their partnership with Girls Inc. In addition to the donation, Allergan is also offering mentoring initiatives and resources to educate and empower future female leaders interest
- Revance’s DaxibotulinumtoxinA for Injection Looks Good in Phase 2 Studies of Forehead Lines and Crow’s Feethttps://modernaesthetics.com/news/revances-daxibotulinumtoxina-for-injection-looks-good-in-phase-2-studies-of-forehead-lines-and-crows-feet/2472963/Revance Therapeutics, Inc.’s next-generation neuromodulator product, DaxibotulinumtoxinA, safely and effectively smoothed forehead lines and Crow’s feet with a median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet achieved in at least one treatment group
- Abbvie’s Allergan: 1, Evolus: O in First Round of Trade Disputehttps://modernaesthetics.com/news/abbvies-allergan-1-evolus-o-in-first-round-of-trade-dispute/2472962/Evolus' and Daewoong Pharma's Jeuveau lost the first round in a trade dispute with AbbVie's Allergan and its Korean partner Medytox that sought to block imports of the Botox rival, but the match is not over yet. AbbVie's Allergan and its Korean partner Medytox
- Endo’s Qwo Scores FDA Nod for Cellulite Treatmenthttps://modernaesthetics.com/news/endos-qwo-scores-fda-nod-for-cellulite-treatment/2472961/The FDA has given its nod to an entirely new way to address cellulite. Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. When fat in cellulite-prone areas swells and e
- Survey: Facial Plastic Surgeons Should Get Ready for the Zoom Boomhttps://modernaesthetics.com/news/survey-facial-plastic-surgeons-should-get-ready-for-the-zoom-boom/2472960/All of that Zoom has led to a boom in requests for facial plastic surgery, according to research published in The Journal of Facial Plastic Surgery and Aesthetic Medicine. The months spent on Zoom and other video conferencing services during the COVID-19 quarantine got a lot of
- Industry Vet Didier Leclercq Joins Aerolase Leadership Teamhttps://modernaesthetics.com/news/industry-vet-didier-leclercq-joins-aerolase-leadership-team/2472958/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med onc
- Candela’s CO2RE Laser Platform Scores Health Canada Approval for Two New Gynecological Indicationshttps://modernaesthetics.com/news/candelas-co2re-laser-platform-scores-health-canada-approval-for-two-new-gynecological-indications/2472955/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a sing